Chenguang Biotech Group (300138) — Net Asset Quality Index
Chenguang Biotech Group (300138) has a Net Asset Quality Index of 42.6% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥7.96 Billion minus total liabilities of CN¥4.57 Billion yields net assets of CN¥3.39 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check financial resilience of Chenguang Biotech Group to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Chenguang Biotech Group Net Asset Quality Index Over Time (2007–2024)
This chart shows how Chenguang Biotech Group's Net Asset Quality Index has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the index stands at 42.6%, representing net assets of CN¥3.39 Billion against total assets of CN¥7.96 Billion CNY. See 300138 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Chenguang Biotech Group (2007–2024)
The table below presents the year-by-year Net Asset Quality Index for Chenguang Biotech Group from 2007 to 2024, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Chenguang Biotech Group stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 35.0% | CN¥3.15 Billion | CN¥9.02 Billion | CN¥5.87 Billion | ▼ -6.4 pp |
| 2023 | 41.4% | CN¥3.53 Billion | CN¥8.54 Billion | CN¥5.01 Billion | ▼ -5.1 pp |
| 2022 | 46.4% | CN¥3.21 Billion | CN¥6.92 Billion | CN¥3.71 Billion | ▼ -0.3 pp |
| 2021 | 46.7% | CN¥2.78 Billion | CN¥5.96 Billion | CN¥3.17 Billion | ▲ +2.5 pp |
| 2020 | 44.2% | CN¥2.06 Billion | CN¥4.65 Billion | CN¥2.59 Billion | ▲ +5.6 pp |
| 2019 | 38.6% | CN¥1.74 Billion | CN¥4.51 Billion | CN¥2.77 Billion | ▼ -13.2 pp |
| 2018 | 51.8% | CN¥1.74 Billion | CN¥3.36 Billion | CN¥1.62 Billion | ▼ -4.7 pp |
| 2017 | 56.5% | CN¥1.62 Billion | CN¥2.87 Billion | CN¥1.25 Billion | ▼ -4.7 pp |
| 2016 | 61.2% | CN¥1.52 Billion | CN¥2.49 Billion | CN¥967.46 Million | ▼ -10.5 pp |
| 2015 | 71.7% | CN¥1.43 Billion | CN¥1.99 Billion | CN¥564.12 Million | ▲ +4.8 pp |
| 2014 | 66.9% | CN¥1.01 Billion | CN¥1.51 Billion | CN¥499.69 Million | ▲ +6.2 pp |
| 2013 | 60.7% | CN¥990.39 Million | CN¥1.63 Billion | CN¥641.26 Million | ▼ -8.3 pp |
| 2012 | 69.0% | CN¥997.86 Million | CN¥1.45 Billion | CN¥447.73 Million | ▼ -17.8 pp |
| 2011 | 86.8% | CN¥968.71 Million | CN¥1.12 Billion | CN¥147.16 Million | ▲ +5.6 pp |
| 2010 | 81.2% | CN¥933.05 Million | CN¥1.15 Billion | CN¥215.92 Million | ▲ +28.9 pp |
| 2009 | 52.3% | CN¥210.67 Million | CN¥402.85 Million | CN¥192.17 Million | ▲ +13.9 pp |
| 2008 | 38.4% | CN¥147.93 Million | CN¥385.24 Million | CN¥237.31 Million | ▼ -15.9 pp |
| 2007 | 54.3% | CN¥101.70 Million | CN¥187.20 Million | CN¥85.49 Million | — |